Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The values for CA125, TPA, IAP, CEA, and ferritin in sera were measured simultaneously in 68 healthy nonpregnant females and 133 patients with various gynecological diseases, and examined by stepwise discriminant analysis. The usefulness and the limits for diagnosis of various gynecological diseases were investigated for each tumor marker. Also, the diagnostic usefulness of stepwise discriminant analysis employing the values for five tumor markers in sera was studied for gynecological malignancies compared with that of measuring serum CA125 alone. Because the mean values for CA125 in sera were increased specifically in the ovarian cancer patient group compared with those of other tumor markers in sera, the measurement of serum CA125 was considered to be more useful in diagnosing ovarian cancer than that of the other tumor markers. The mean values for CA125 in sera, however, were also increased more significantly in the groups of patients with endometriosis and normal pregnancies than in the group of healthy nonpregnant females (p less than 0.005). In the stepwise discriminant analysis employing the values for CA125 and four other tumor markers in sera, the diagnostic usefulness of each tumor marker was demonstrated in the early diagnosis, the differential diagnosis, and the determination of complete remission after several therapies for ovarian cancers.
 ...
PMID:[Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms]. 299 49

A prospective study was conducted on 50 women with ovarian cancer to determine the association of elevated serum ferritin and ovarian cancer and its potential as a tumor marker. The controls consisted of 116 healthy volunteers, 51 patients with benign gynecologic tumors and 15 patients with benign liver disease. The mean ferritin level in patients with ovarian cancer was 436.7 ng/mL, significantly higher than that in the controls. The effect of chronology on the serum ferritin was also investigated. Hyperferritinemia was observed in 25 (50.0%) of 50 patients with ovarian carcinoma. In patients with liver metastases a marked increase in ferritin was noted. The rate of ferritin elevation in patients with epithelial carcinoma and no hepatic involvement was 21.4%.
 ...
PMID:Hyperferritinemia in ovarian cancer. 335 17

The levels of CA125, TPA, IAP, CEA, and ferritin in the serum were measured simultaneously in 68 healthy nonpregnant females and 133 patients with various gynecological diseases, and were subjected to statistical discriminant analysis for the diagnosis of ovarian cancer. The usefulness and the limits for diagnosis of various gynecological diseases were investigated for each tumor marker. Also, the diagnostic usefulness of the stepwise discriminant analysis employing the values of these five tumor markers in the serum in cases of ovarian cancer was compared with that of CA125 measurements alone. Because the frequency of cases with an elevated serum CA125 level increased more specifically in the ovarian cancer group than those of other tumor makers in the serum, this parameter was considered to be more useful for the diagnosis of ovarian cancer than the levels of the other tumor markers. The frequencies of cases with the elevated serum CA125 levels, however, also increased in the groups of patients with endometriosis and at an early stage of normal pregnancy more than in the group of healthy nonpregnant females. In the ovarian cancer patients, the discriminant analysis employing the values of CA125 and four other tumor markers in sera was more useful for early diagnosis, differential diagnosis, early detection of recurrences, and the determination of complete remission after therapy than the measurement of the serum CA125 level alone.
 ...
PMID:Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer. 342 8

The tumour markers carcinoembryonic antigen (CEA), ferritin, cancer antigen 125 (CA 125) and tissue polypeptide antigen (TPA) were measured by radioimmunoassay in sera from 80 patients with ovarian cancer pre-operatively, postoperatively, during cytostatic chemotherapy and on follow up. Discriminant analysis was applied to obtain retrospective classification of 60 patients into a group showing a favourable course of the disease (no recurrence, tumour regression) and into a group with an unfavourable course (recurrence, progression of the tumour). The classification was based on the introduction of the Cutting Score. By means of this bio-mathematical model it was possible to make at least a short-term prognostic statement in a further 20 patients. It is suggested that invasive diagnostic procedures may not be required in patients who are found to have normal tumour marker levels.
 ...
PMID:[Predictive value of a tumor marker combination for the monitoring of ovarian cancer]. 346 Feb 73

The serum levels of CA 125 and CA 19-9 were determined by an immunoradiometric assay employing the monoclonal antibody OC 125 and anti-CA 19-9 antibody in 88 patients with ovarian carcinoma. When a cut-off value of CA 125 was set below 35 U/ml in the control group, serum elevated levels of CA 125 were found in 86.7% of the patients with surgically demonstrable ovarian serous cystadenocarcinoma, in 100% (4/4 cases) of clear-cell carcinoma, in 50% (2/4 cases) of endometrioid carcinoma, in 100% (5/5 cases) of undifferentiated carcinoma, and in 80% of the recurrent cases. Using a cut-off value of 37 U/ml, serum elevated levels of CA 19-9 were detected in 68.2% of mucinous cystadenocarcinoma, in 28.9% of serous cystadenocarcinoma, in 75% (3/4 cases) of metastatic ovarian carcinoma, and in 37.5% of the recurrent cases. A statistical analysis of the combination assay using CA 125, CA 19-9, tissue polypeptide antigen (TPA), immunosuppressive acidic protein (IAP), ferritin and CEA was carried out by multivariate method (discriminatory analysis) in 45 patients with ovarian carcinoma and 50 healthy subjects. As a result before treatment, positive rates of a single tumor marker were 79.7% with CA 125, 42.7% with CA-19-9, 73.1% with IAP, 61.7% with TPA, 64.3% with ferritin and 25.4% with CEA, respectively. A combination assay of these markers was useful for detecting identification of ovarian carcinoma, by which it gave a higher accuracy of ovarian cancer detection.
 ...
PMID:Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. 347 96

To evaluate the predictive value of the serial determination of various tumor markers, we measured carcinoembryonic antigen, ferritin, cancer antigen 125, and tissue polypeptide antigen in 109 patients with ovarian cancer before surgery, during postoperative chemotherapy, and follow-up. From these patients two groups were randomly selected. Group 1 (30 patients) had a favorable course, and Group 2 (30 patients) had an unfavorable course. Using the discriminant analysis we calculated a linear discriminant function and a cut-off score. The two groups were thereby separated according to their scores (characteristic values) from their marker values. The scores accurately reflected the clinical course in 55 of the 60 patients (91.7%). This discriminant function was then used to make a prognosis in 49 patients. In 21 patients an elevated characteristic value (greater than or equal to cut-off score) indicated disease progression 5 months before clinical confirmation was possible. The remaining 28 patients scored below the cut-off point. From six to 65 months (mean, 26.2) after surgery all are free of recurrence. It is concluded that invasive procedures, second-look laparotomy, for instance, may not be necessary in following up ovarian cancer patients with normal tumor marker profiles.
 ...
PMID:The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. 348 57

A four-fold (P less than 0.001) mean increase in iron levels was found in 18 patients (a total of 36 courses of therapy) with ovarian cancer at the end of a 5-day course of cisplatin (40 mg/m2 per day every 4-5 weeks). The kinetics of these modifications began very early (24-48 h after initiation of therapy): they reached their maximum on the 4th-5th day, coinciding with the last drug administration, and basal levels were recovered after the 10th day. A subsequent eight-fold average increase (P less than 0.001) in ferritin serum levels, beginning 2 days after the iron changes, was observed, but showed a slower regression (after the 15th day). Reticulocyte counts were lowered (P less than 0.001) with the same time-course of the iron increases, but returned to pretreatment levels within 2 weeks. Total bilirubin and serum glutamate-pyruvate transaminase showed significantly delayed increases compared with iron. The results are in keeping with a reduced iron utilization by the erythroid precursors, but other mechanisms cannot be excluded. There is no statistical correlation between the early iron increases and the subsequent hemoglobin nadir values.
 ...
PMID:Changes in serum iron levels following very high-dose cisplatin. 358 20

Ferritin levels in extracts of tumor tissue and serum of patients with gynecological malignancies were assayed by immunodiffusion methods using a standard system of testing for ferritin. A high blood-ferritin level (500-1,000 ng/ml) was found in 8 out 21 patients with ovarian cancer, 8 out of 24 patients with endometrial carcinoma. 2 out of 8 cases of mucinous cystadenoma and in 2 out of 4 cases of pyoovarium. It was lower in other malignancies of the female genital tract. There was no correlation between the ferritin level of blood serum and that of tumor tissue extracts. Although blood serum ferritin was found in very few healthy subjects (2.5%), it is suggested that blood-ferritin level test should be carried out in the course of examination of slowly-progressing purulent adnexitis and mass screening for tumors of female genitals.
 ...
PMID:[Ferritin study in tumors of the female genitalia]. 640 1

Serum and tissue ferritins were quantitated by a radioimmunoassay kit (SPAC KIT, Daiichi Radioisotope Lab.) and a diagnostic implication of serum ferritins in patients with gynecological diseases was evaluated. In order to investigate the potential use of tumor marker as a feto-placental antigen (protein), ferritin from ovarian cancer was compared with ferritins from normal adult and feto-placental organs. Serum ferritin levels were significantly higher (p less than 0.01) in patients with ovarian adenocarcinoma, Krukenberg's tumor, cervical squamous cell carcinoma and other malignant diseases than in normal women. Among adult organs the kidney and spleen showed the highest and the heart the lowest ferritin content. The ferritin contents of the kidney and spleen were 78.4 micrograms and 76.2 micrograms/g wet weight, respectively and that of the heart was 5.7 micrograms/g wet weight. The ferritin contents of other adult organs ranged from 10 to 25 micrograms/g wet weight. On the other hand the placenta showed the highest and the heart and stomach the lowest ferritin content among feto-placental organs. The ferritin content of the placenta was 7 micrograms/g wet weight. The ferritin contents of other fetal organs were only half as in the placenta. The ferritin contents of ovarian cancers ranged 6 to 8 micrograms/g wet weight and was almost identical to that of the placenta.
 ...
PMID:[Gynecological cancer and ferritin--a study on the carcinofetoplacental ferritin]. 682 63

We investigated the relationship between immunosuppressive acidic protein (IAP), an immunosuppressive substance determined in the body fluid from patients with cancer and the stages of cancer, and also its relationship with the progress of cancer during treatment and convalescence in 42 cases of ovary cancer, 47 cases of cancer of the uterine neck, 19 cases of cancer of the uterine body, and 5 cases of other of cancers. In addition, the relationship of IAP with other immunosuppressive substances and cell-mediated immunities was also investigated. The IAP level in the serum was not useful for early diagnosis of gynecologic malignant tumors, but it reflected on stages of cancer more accurately compared to levels of other immunosuppressive substances in the serum: alpha-antitripsine (alpha AT), alpha-glyco-protein (alpha AG), carcinoembrionic antigen (CEA), c-reactive protein (CRP), and serum ferritin (s-Fer), were useful as parameters showing progress of cancer during treatment and convalescence. The IAP level in the peritoneal fluid showed the same tendency. For the relationship with cell-mediated immunity, a stimulate index (SI) showed an inverse correlation from stage I; a T-cell count exhibited the same tendency; IgGFcR+ T-cell count showed a positive correlation in stage III; and ADCC exhibited an inverse correlation in stage III. However, immunosuppressive substances including IAP show high levels also in inflammatory diseases. Therefore, an appreciative value of IAP in the clinical area increases by being used for monitoring gynecologic cancer patients in combination with indicators of cell-mediated immunity, particularly, with SI.
 ...
PMID:[Immunosuppressive acidic protein (IAP) in gynecologic malignant tumors and its relationship with other immunosuppressive substances and cell-mediated immunity]. 688 75


<< Previous 1 2 3 Next >>